Longevity Gene Therapy Intel — July 2026

• The science moved; your access did not. VERVE-102 published in NEJM — one-and-done PCSK9 base editing is now clinically validated in humans, up to 62% LDL-C reduction durable to 18 months. confirmed
• You still qualify for nothing. Every open in vivo lipid-editing trial (Verve, Editas, CRISPR Tx) enrols HeFH or established/premature ASCVD. You have neither — no pathogenic LDLR/APOB/PCSK9 variant, CAC = 0.
• Your Lp(a) of 90 nmol/L is below every trial threshold too (Lp(a) studies enrol at ≥175–200 nmol/L). You are excluded on the low side, which is a good problem.
• Practical read: gene editing is a 2030+ option for you, not a 2026 one. The modifiable number this quarter remains ApoB 1.08 g/L (108 mg/dL) via conventional therapy.
• One thing to watch: VERVE-102 Phase 2 opens by end-2026. If Lilly broadens eligibility beyond HeFH to elevated-ApoB primary prevention, that is your first realistic entry point.

Prioritised

• HIGH — Do not defer lipid therapy waiting on gene editing. The earliest plausible approval for a PCSK9 base editor is post-2029; VERVE-102 has not yet started Phase 2 (Lilly, 25 May 2026 — confirmed). At ApoB 1.08 g/L and LDL-C 4.24 mmol/L (164 mg/dL), three-plus years of untreated particle-years is the dominant risk, not the absence of a one-shot cure.
• HIGH — Raise with Dr. Saya: ask for a formal cascade-screening view on HeFH. Not because you have it — Nucleus found no pathogenic variant — but because documented exclusion closes the question permanently and reframes your target as ApoB-driven primary prevention rather than trial-chasing. inferred
• MEDIUM — Diarise the VERVE-102 Phase 2 protocol posting (expected Q4 2026). The single variable that matters is whether inclusion widens from HeFH/premature CAD to "elevated ApoB despite maximally tolerated oral therapy." If it does, you plausibly qualify; if it does not, deprioritise Verve for 24 months.
• LOW — No action on Lp(a) gene editing. CTX320 is still dose-finding and your Lp(a) of 90 nmol/L sits well under enrolment thresholds. This is already covered by the monthly Lp(a) therapy monitor — no duplicate tracking needed.
• LOW — Ignore reprogramming for clinical purposes. Altos has no human programme; the only cleared reprogramming trial is intraocular. Nothing systemic, nothing relevant to you this decade.

Why "one-and-done" PCSK9 editing matters more for you than the percentage suggests

• Cumulative particle-years, not peak LDL-C, drive plaque initiation. Your discordance — ApoB 1.08 g/L with Total CAC = 0 — means you are accumulating atherogenic particle exposure without yet having converted it to calcified plaque. CAC = 0 is a statement about past burden that has already calcified, not about current soft-plaque flux. A therapy that removes 60% of LDL-C for life, rather than for as long as adherence holds, changes the integral rather than the instantaneous value.
• Base editing vs nuclease editing. VERVE-102 uses an adenine base editor to install a single A•T→G•C change in PCSK9, creating a splice-disrupting or nonsense-equivalent lesion without a double-strand break. EDIT-401 uses Cas12a, which does cut. The clinical significance is off-target and chromosomal-rearrangement risk: base editing avoids DSB-mediated translocations, which is why it reached humans first despite Cas12a's superior multiplexing. inferred from mechanism
• Why EDIT-401 hits Lp(a) and VERVE-102 does not. PCSK9 knockdown upregulates hepatic LDL receptor recycling, clearing ApoB-100 particles — but Lp(a) clearance is only partially LDLR-dependent, which is why PCSK9 inhibitors drop Lp(a) by a modest ~25–30% rather than proportionally training data — not re-verified this scan. Editas reports ~90% reductions across LDL-C, Lp(a) and ApoB in primates, implying a target upstream of, or parallel to, LDLR-mediated clearance. For a patient with two elevated atherogenic axes, that matters. inferred
• The exclusion logic is regulatory, not biological. You are excluded from every one of these trials because first-in-human gene-editing studies must enrol populations where the risk/benefit ratio is unambiguous — HeFH patients with a lifetime of untreated LDLR dysfunction. Primary-prevention patients with moderately elevated ApoB and CAC = 0 are the last population an editing programme will enrol, because the counterfactual is simply taking a statin. That ordering will not change until post-approval label expansion, realistically 2030–2032.
• Interaction to keep in view. You are on a GH secretagogue (CJC-1295/Ipamorelin), which is insulin-antagonistic and can drift HbA1c upward from your current 5.6%. None of the lipid-editing programmes interact with that axis, but a rising HbA1c would independently worsen your ASCVD risk profile and would also become an exclusion criterion in some future trials. Keep the HbA1c monitoring cadence.

• EDIT-401 first human data, end-2026. If the ~90% triple reduction in LDL-C/Lp(a)/ApoB translates to humans even at half that magnitude, this becomes the single most phenotype-relevant asset in the field for you. confirmed guidance
• VERVE-102 Phase 2 protocol, Q4 2026. Watch inclusion criteria specifically. confirmed guidance
• CTX321 — next-generation LPA guide RNA, ~2× preclinical potency on the same LNP delivery system. Suggests CRISPR Tx is iterating rather than abandoning the Lp(a) target. confirmed
• HORIZON (pelacarsen) outcomes readout expected before end-2026 — the first test of whether lowering Lp(a) actually reduces cardiovascular events. This is the gating question for the entire Lp(a) field, including CTX320. Amgen has pushed its own pivotal timing update to early 2027. confirmed
• Altos Labs — CMO appointment implies a clinical programme announcement is plausible within 12–24 months. Nothing to act on until an indication is disclosed. inferred

• Intellia Therapeutics — strong Phase 3 progress, but still no cholesterol or metabolic programme announced. Platform validation only.
• Altos Labs — no disclosed clinical programme; no publications surfaced this quarter that change the clinical picture.
• CRISPR Therapeutics CTX320 — guidance unchanged; the promised H1 2026 dose-finding data could not be confirmed as released.